Advertisement

Outcomes of Drug-Eluting Stents for Protected Left Main Coronary Artery Disease (from the Multicenter, United States DEScover Registry)

Published:November 28, 2011DOI:https://doi.org/10.1016/j.amjcard.2011.09.038
      Percutaneous coronary intervention (PCI) for protected left main coronary artery (PLM) disease is complex because of patient and lesion factors; however, limited data exist on the outcomes of drug-eluting stent (DES) use for this indication. DEScover is a prospective observational study that enrolled consecutive patients with PCI in 2005. In-hospital and 1-year statuses were analyzed for 6,172 patients treated with DES according to LM and coronary artery bypass grafting (CABG) statuses (PLM, n = 93; previous CABG native vessel non-LM, n = 722; no previous CABG, n = 5,357). Cumulative event rates were calculated by the Kaplan–Meier method. Cox proportional hazards regression was used for multivariable analysis of adverse events. Baseline clinical, angiographic, and procedural variables differed significantly among groups, with patients with previous CABG, PLM, and non-LM having higher risk characteristics. In patients with previous CABG, after adjustment with CABG non-LM as a reference group, there were no significant differences in 1-year risk of any adverse event except a trend toward a greater risk of myocardial infarction (MI) in patients with PLM (adjusted hazard ratio 2.4, confidence interval 0.95 to 6.2, p = 0.06). However, patients after CABG (PLM and non-LM) compared to patients without previous CABG had a similar adjusted risk of death, MI, and stent thrombosis; an increased risk of target lesion revascularization (adjusted hazard ratio 1.79, confidence interval 1.2 to 2.6, p = 0.003), target vessel revascularization and death/MI/target vessel revascularization; and a lower risk of CABG (adjusted hazard ratio 0.25, confidence interval 0.09 to 0.67, p = 0.006). In conclusion, status after CABG rather than PLM location increases the risk of repeat revascularization with PCI in DES-treated patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Christenson J.T.
        • Schmuziger M.
        • Simonet F.
        Reoperative coronary artery bypass procedures: risk factors for early mortality and late survival.
        Eur J Cardiothorac Surg. 1997; 11: 129-133
        • Weintraub W.S.
        • Jones E.L.
        • Morris D.C.
        • King III, S.B.
        • Guyton R.A.
        • Craver J.M.
        Outcome of reoperative coronary bypass surgery versus coronary angioplasty after previous bypass surgery.
        Circulation. 1997; 95: 868-877
        • Kelley M.P.
        • Klugherz B.D.
        • Hashemi S.M.
        • Meneveau N.F.
        • Johnston J.M.
        • Matthai Jr, W.H.
        • Banka V.S.
        • Herrmann H.C.
        • Hirshfeld Jr, J.W.
        • Kimmel S.E.
        • Kolansky D.M.
        • Horwitz P.A.
        • Schiele F.
        • Bassand J.P.
        • Wilensky R.L.
        One-year clinical outcomes of protected and unprotected left main coronary artery stenting.
        Eur Heart J. 2003; 24: 1554-1559
        • Tan W.A.
        • Tamai H.
        • Park S.J.
        • Plokker H.W.
        • Nobuyoshi M.
        • Suzuki T.
        • Colombo A.
        • Macaya C.
        • Holmes Jr, D.R.
        • Cohen D.J.
        • Whitlow P.L.
        • Ellis S.G.
        • ULTIMA Investigators
        Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients.
        Circulation. 2001; 104: 1609-1614
        • Biondi-Zoccai G.G.
        • Lotrionte M.
        • Moretti C.
        • Meliga E.
        • Agostoni P.
        • Valgimigli M.
        • Migliorini A.
        • Antoniucci D.
        • Carrié D.
        • Sangiorgi G.
        • Chieffo A.
        • Colombo A.
        • Price M.J.
        • Teirstein P.S.
        • Christiansen E.H.
        • Abbate A.
        • Testa L.
        • Gunn J.P.
        • Burzotta F.
        • Laudito A.
        • Trevi G.P.
        • Sheiban I.
        A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease.
        Am Heart J. 2008; 155: 274-283
        • Khattab A.A.
        • Hamm C.W.
        • Senges J.
        • Toelg R.
        • Geist V.
        • Bonzel T.
        • Kelm M.
        • Levenson B.
        • Neumann F.J.
        • Nienaber C.A.
        • Pfannebecker T.
        • Sabin G.
        • Schneider S.
        • Tebbe U.
        • Richardt G.
        • German Cypher R.
        Sirolimus-eluting stent treatment for unprotected versus protected left main coronary artery disease in widespread clinical routine: 6-month and 3-year clinical follow-up results from the prospective multicentre German Cypher Registry.
        Heart. 2007; 93: 1251-1255
        • Beohar N.
        • Davidson C.J.
        • Kip K.E.
        • Goodreau L.
        • Vlachos H.A.
        • Meyers S.N.
        • Benzuly K.H.
        • Flaherty J.D.
        • Ricciardi M.J.
        • Bennett C.L.
        • Williams D.O.
        Outcomes and complications associated with off-label and untested use of drug-eluting stents.
        JAMA. 2007; 297: 1992-2000
        • Williams D.O.
        • Abbott J.D.
        • Kip K.E.
        • DEScover Investigators
        Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry.
        Circulation. 2006; 114: 2154-2162
        • Pandya S.B.
        • Kim Y.H.
        • Meyers S.N.
        • Davidson C.J.
        • Flaherty J.D.
        • Park D.W.
        • Mediratta A.
        • Pieper K.
        • Reyes E.
        • Bonow R.O.
        • Park S.J.
        • Beohar N.
        Drug-eluting versus bare-metal stents in unprotected left main coronary artery stenosis a meta-analysis.
        JACC Cardiovasc Interv. 2010; 3: 602-611
        • Abbott J.D.
        • Voss M.R.
        • Nakamura M.
        • Cohen H.A.
        • Selzer F.
        • Kip K.E.
        • Vlachos H.A.
        • Wilensky R.L.
        • Williams D.O.
        Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry.
        J Am Coll Cardiol. 2007; 50: 2029-2036
        • Valgimigli M.
        • Malagutti P.
        • Rodriguez-Granillo G.A.
        • Garcia-Garcia H.M.
        • Polad J.
        • Tsuchida K.
        • Regar E.
        • Van der Giessen W.J.
        • de Jaegere P.
        • De Feyter P.
        • Serruys P.W.
        Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registries.
        J Am Coll Cardiol. 2006; 47: 1530-1537